| Item Type | Name |
|
Concept
|
Cholesterol Esters
|
|
Concept
|
Insulin
|
|
Concept
|
Esterification
|
|
Concept
|
Esters
|
|
Concept
|
Insulin Coma
|
|
Concept
|
Insulin Resistance
|
|
Concept
|
1-Alkyl-2-acetylglycerophosphocholine Esterase
|
|
Concept
|
Cholesterol Ester Transfer Proteins
|
|
Academic Article
|
Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial.
|
|
Academic Article
|
Effect of marine lipids on cholesteryl ester transfer and lipoprotein composition in patients with hypercholesterolemia.
|
|
Academic Article
|
Fiber intake and risk of developing non-insulin-dependent diabetes mellitus.
|
|
Academic Article
|
Safety and pharmacokinetic study with escalating doses of 3-acetyl-7-oxo-dehydroepiandrosterone in healthy male volunteers.
|
|
Academic Article
|
Effects of continuous estrogen and estrogen-progestin replacement regimens on cardiovascular risk markers in postmenopausal women.
|
|
Academic Article
|
Lipid responses to plant-sterol-enriched reduced-fat spreads incorporated into a National Cholesterol Education Program Step I diet.
|
|
Academic Article
|
Safety and tolerability of esterified phytosterols administered in reduced-fat spread and salad dressing to healthy adult men and women.
|
|
Academic Article
|
The safety and immunogenicity of a CETP vaccine in healthy adults.
|
|
Academic Article
|
Therapeutic interventions targeted at the augmentation of reverse cholesterol transport.
|
|
Academic Article
|
Inhaled human insulin: an inspiration for patients with diabetes mellitus?
|
|
Academic Article
|
Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin.
|
|
Academic Article
|
The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study.
|
|
Academic Article
|
Biologic therapies for dyslipidemia.
|
|
Academic Article
|
Baseline lipoprotein lipids and low-density lipoprotein cholesterol response to prescription omega-3 acid ethyl ester added to Simvastatin therapy.
|
|
Academic Article
|
Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels.
|
|
Academic Article
|
Low high-density lipoprotein cholesterol and increased cardiovascular disease risk: an analysis of statin clinical trials.
|
|
Academic Article
|
Novel targets that affect high-density lipoprotein metabolism: the next frontier.
|
|
Academic Article
|
Underappreciated opportunities for low-density lipoprotein management in patients with cardiometabolic residual risk.
|
|
Academic Article
|
Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines.
|
|
Academic Article
|
Safety of anacetrapib in patients with or at high risk for coronary heart disease.
|
|
Academic Article
|
Relation of diurnal blood pressure variation and triglyceride-to-high-density lipoprotein cholesterol ratio in patients without diabetes mellitus.
|
|
Academic Article
|
Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker.
|
|
Academic Article
|
Lp-PLA2: A new target for statin therapy.
|
|
Academic Article
|
Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib.
|
|
Academic Article
|
Focus on HDL as a therapeutic target for CAD risk reduction.
|
|
Academic Article
|
Effects of prescription omega-3-acid ethyl esters on lipoprotein particle concentrations, apolipoproteins AI and CIII, and lipoprotein-associated phospholipase A(2) mass in statin-treated subjects with hypertriglyceridemia.
|
|
Academic Article
|
Peripheral artery disease, biomarkers, and darapladib.
|
|
Academic Article
|
Efficacy and safety of dalcetrapib in type 2 diabetes mellitus and/or metabolic syndrome patients, at high cardiovascular disease risk.
|
|
Academic Article
|
Plasminogen activator inhibitor-1 and the risk of Type 2 diabetes mellitus in American Indians: the Strong Heart Study.
|
|
Academic Article
|
Update on CETP inhibition.
|
|
Academic Article
|
Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia.
|
|
Academic Article
|
Measurement of LDL-C after treatment with the CETP inhibitor anacetrapib.
|
|
Academic Article
|
Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease?
|
|
Academic Article
|
A novel omega-3 free fatty acid formulation has dramatically improved bioavailability during a low-fat diet compared with omega-3-acid ethyl esters: the ECLIPSE (Epanova(®) compared to Lovaza(®) in a pharmacokinetic single-dose evaluation) study.
|
|
Academic Article
|
American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement--executive summary.
|
|
Academic Article
|
Steady-state bioavailability of prescription omega-3 on a low-fat diet is significantly improved with a free fatty acid formulation compared with an ethyl ester formulation: the ECLIPSE II study.
|
|
Academic Article
|
Assessment of the effect of esterified propoxylated glycerol (EPG) on the status of fat-soluble vitamins and select water-soluble nutrients following dietary administration to humans for 8 weeks.
|
|
Academic Article
|
Effects of anacetrapib on plasma lipids in specific patient subgroups in the DEFINE (Determining the Efficacy and Tolerability of CETP INhibition with AnacEtrapib) trial.
|
|
Academic Article
|
Effect of colesevelam and niacin on low-density lipoprotein cholesterol and glycemic control in subjects with dyslipidemia and impaired fasting glucose.
|
|
Academic Article
|
Evaluation of lipids, drug concentration, and safety parameters following cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib in patients with or at high risk for coronary heart disease.
|
|
Academic Article
|
Measurement of reverse cholesterol transport pathways in humans: in vivo rates of free cholesterol efflux, esterification, and excretion.
|
|
Academic Article
|
Sucrose-induced cardiomyocyte dysfunction is both preventable and reversible with clinically relevant treatments.
|
|
Academic Article
|
Severity of symptoms in chronically institutionalized geriatric schizophrenic patients.
|
|
Academic Article
|
Lipid-induced insulin resistance is associated with increased monocyte expression of scavenger receptor CD36 and internalization of oxidized LDL.
|
|
Academic Article
|
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM--2015 EXECUTIVE SUMMARY.
|
|
Academic Article
|
LIMITATIONS IN THE USE OF ORAL HYPOGLYCEMIC AGENTS IN JUVENILE PATIENTS WITH DIABETES.
|
|
Academic Article
|
AACE/ACE comprehensive diabetes management algorithm 2015.
|
|
Academic Article
|
Systemic Bioavailability and Dose Proportionality of Omega-3 Administered in Free Fatty Acid Form Compared With Ethyl Ester Form: Results of a Phase 1 Study in Healthy Volunteers.
|
|
Academic Article
|
Short-term effects of coping skills training as adjunct to intensive therapy in adolescents.
|
|
Academic Article
|
Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial.
|
|
Academic Article
|
Comparison of low-density lipoprotein cholesterol equations in patients with dyslipidaemia receiving cholesterol ester transfer protein inhibition.
|
|
Academic Article
|
Obicetrapib: Reversing the Tide of CETP Inhibitor Disappointments.
|